Results 91 to 100 of about 1,350,711 (248)

HOSPITAL-ACQUIRED URINARY TRACT INFECTIONS IN CANCER PATIENTS

open access: yesСибирский онкологический журнал, 2017
Introduction. Urinary tract infections are among the most frequently seen bacterial infections. Worldwide, about 150 million people are diagnosed with urinary tract infections each year, costing the global economy in excess of 3.5 billion US dollars ...
N. V. Dmitrieva   +9 more
doaj   +1 more source

Long-term management and prevention of urinary tract infections in children

open access: yes, 2010
Urinary tract infection (UTI) is a frequently occurring clinical problem in childhood. Upper urinary tract infections (ie, acute pyelonephritis) may lead to renal scarring, hypertension, and end-stage renal dysfunction.
Hoberman, Alejandro, Shaikh, Nader
core  

Antibiotic prophylaxis for urinary tract infections after removal of urinary catheter: meta-analysis [PDF]

open access: yes, 2013
Objective To determine whether antibiotic prophylaxis at the time of removal of a urinary catheter reduces the risk of subsequent symptomatic urinary tract infection. Design Systematic review and meta-analysis of studies published before November 2012
Carpenter, C. R.   +6 more
core   +2 more sources

Female Older Adults Awareness Regarding Recurrent Lower Urinary Tract Infections [PDF]

open access: yesEgyptian Journal of Health Care
Background: Urinary tract infections are more common in females and predominantly based on their unhealthy reported practices in their day to day lives.
Salwa Shabban Ali   +2 more
doaj   +1 more source

Clinical features and diagnosis of urinary tract infections in infants and children older than one month

open access: yes, 2010
Urinary tract infections (UTI) are a common and important clinical problem in childhood. Upper urinary tract infections (ie, acute pyelonephritis) may lead to renal scarring, hypertension, and end-stage renal disease.
Hoberman, Alejandro, Shaikh, Nader
core  

Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From a Phase 2a, Multicenter, Randomized, Double‐Blind, Proof‐of‐Concept Study

open access: yesArthritis &Rheumatology, EarlyView.
Objective To assess guselkumab + golimumab combination therapy versus guselkumab monotherapy in participants with active psoriatic arthritis (PsA) and inadequate response to tumor necrosis factor inhibitors (TNFi‐IR). Methods Adults with active TNFi‐IR PsA (three or more tender/swollen joints) were randomized (2:1) to subcutaneous guselkumab (100 mg) +
Jose U. Scher   +12 more
wiley   +1 more source

Prevalence and Pattern of Microbial Resistance of Urinary Pathogens Resistant to Quinolones [PDF]

open access: yesBeyhagh
Background and Aim: Urinary tract infection is an infection in any part of the urinary system including kidneys, ureters, bladder and urethra. Most infections involve the lower urinary tract such as the bladder and urethra. Women are more susceptible to
Zeinab Siami
doaj  

Integrated Clinical and Proteomic Profiling of CD19 Chimeric Antigen Receptor T Cell Therapy in Progressive Systemic Sclerosis

open access: yesArthritis &Rheumatology, EarlyView.
Objective To characterize the clinical, immunologic, and proteomic changes associated with CD19 chimeric antigen receptor T cell therapy in patients with progressive systemic sclerosis (SSc). Methods Patients with progressive SSc received CD19 chimeric antigen receptor (CAR)‐T cell therapy and were observed longitudinally for safety, clinical efficacy,
Chenhan Jia   +16 more
wiley   +1 more source

Postoperative urinary tract infections following flexible ureteroscopy: a prospective cohort study in the West bank of Palestine

open access: yesBMC Urology
Background Reports on the incidence of urinary tract infections following flexible ureteroscopy in Palestine are scarce. This study aimed to assess the incidence of urinary tract infections after flexible ureteroscopy and to identify the risk factors ...
Aaisha Mhamid   +5 more
doaj   +1 more source

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety Up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA‐2 Trial

open access: yesArthritis &Rheumatology, EarlyView.
Objective To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease‐modifying antirheumatic drugs or received tumor necrosis factor inhibitors. Methods In the 52‐week, double‐blind, placebo‐controlled, phase 3 Program for Evaluation
Philip J. Mease   +20 more
wiley   +1 more source

Home - About - Disclaimer - Privacy